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Genetic diagnosis of developmental disorders in the 
DDD study: a scalable analysis of genome-wide research data
Caroline F Wright, Tomas W Fitzgerald, Wendy D Jones, Stephen Clayton, Jeremy F McRae, Margriet van Kogelenberg, Daniel A King, 
Kirsty Ambridge, Daniel M Barrett, Tanya Bayzetinova, A Paul Bevan, Eugene Bragin, Eleni A Chatzimichali, Susan Gribble, Philip Jones, 
Netravathi Krishnappa, Laura E Mason, Ray Miller, Katherine I Morley, Vijaya Parthiban, Elena Prigmore, Diana Rajan, Alejandro Sifrim, 
G Jawahar Swaminathan, Adrian R Tivey, Anna Middleton, Michael Parker, Nigel P Carter, Jeff rey C Barrett, Matthew E Hurles, David R FitzPatrick, 
Helen V Firth, on behalf of the DDD study* 
Summary
Background Human genome sequencing has transformed our understanding of genomic variation and its relevance 
to health and disease, and is now starting to enter clinical practice for the diagnosis of rare diseases. The question of 
whether and how some categories of genomic fi ndings should be shared with individual research participants is 
currently a topic of international debate, and development of robust analytical workfl ows to identify and communicate 
clinically relevant variants is paramount.
Methods The Deciphering Developmental Disorders (DDD) study has developed a UK-wide patient recruitment 
network involving over 180 clinicians across all 24 regional genetics services, and has performed genome-wide 
microarray and whole exome sequencing on children with undiagnosed developmental disorders and their parents. 
After data analysis, pertinent genomic variants were returned to individual research participants via their local clinical 
genetics team.
Findings Around 80 000 genomic variants were identifi ed from exome sequencing and microarray analysis in each 
individual, of which on average 400 were rare and predicted to be protein altering. By focusing only on de novo and 
segregating variants in known developmental disorder genes, we achieved a diagnostic yield of 27% among 
1133 previously investigated yet undiagnosed children with developmental disorders, whilst minimising incidental 
fi ndings. In families with developmentally normal parents, whole exome sequencing of the child and both parents 
resulted in a 10-fold reduction in the number of potential causal variants that needed clinical evaluation compared to 
sequencing only the child. Most diagnostic variants identifi ed in known genes were novel and not present in current 
databases of known disease variation.
Interpretation Implementation of a robust translational genomics workfl ow is achievable within a large-scale rare 
disease research study to allow feedback of potentially diagnostic fi ndings to clinicians and research participants. 
Systematic recording of relevant clinical data, curation of a gene–phenotype knowledge base, and development of 
clinical decision support software are needed in addition to automated exclusion of almost all variants, which is 
crucial for scalable prioritisation and review of possible diagnostic variants. However, the resource requirements of 
development and maintenance of a clinical reporting system within a research setting are substantial.
Funding Health Innovation Challenge Fund, a parallel funding partnership between the Wellcome Trust and the UK 
Department of Health.
Copyright © Wright et al. Open Access article distributed under the terms of CC BY. 
Introduction
The increasing use of whole exome and whole genome 
sequencing in both research1,2 and clinical practice3–5 raises 
questions about how to maximise the diagnostic 
usefulness of genomic data and how to share results with 
research participants and patients. Furthermore, it is 
increasingly deemed ethically desirable to return clinically 
useful results to research participants.6 However, return of 
individual genomic results poses major logistical 
challenges. A robust workfl ow must be developed to track 
individual samples and datasets, generate high-quality 
genomic data, fi lter out a very large number of probably 
benign variants, prioritise plausibly pathogenic variants, 
and link these fi ndings to individual clinical data for 
interpretation and appropriate clinical follow-up. 
Health-related fi ndings from a human genome could 
potentially include thousands of variants pertaining to 
hundreds of diff erent conditions,7 almost none of which 
provide clinically useful information for a specifi c 
individual.8 A fi rst step toward addressing these challenges 
is to separate potential genomic fi ndings into those that 
are pertinent to a particular disease investigation and 
those that are non-pertinent (or incidental) to that disease. 
Although many commentators have debated the merits of 
returning diff erent classes of fi ndings from large research 
studies and biobanks,6,9,10 none has yet provided a scalable 
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See Online for appendix 1 implementation from patient identifi cation through to a 
confi rmed diagnosis within a research context. Here we 
describe the development and implementation of a 
translational genomics workfl ow in a large-scale rare 
disease research study to communicate pertinent fi ndings 
to individual research participants, whilst minimising 
incidental fi ndings.
The Deciphering Developmental Disorders (DDD) 
study11 is a UK-wide collaborative project that seeks to 
facilitate the translation of genomic sequencing 
technologies into the National Health Service (NHS), by 
collecting a set of high-resolution genomic and phenotypic 
data for children with severe undiagnosed developmental 
disorders and their parents. Although whole genome 
microarray analysis has already proven invaluable 
for identifi cation of large pathogenic copy number 
variants (mostly deletions and duplications) in children 
with developmental disorders,12 most children remain 
undiagnosed. In many cases, the condition is caused by 
a de novo mutation that occurs spontaneously in the 
aff ected child somewhere in the genome,13–15 and if there is 
no family history of the condition the genetic basis of the 
diagnosis can be easily overlooked. The recruitment 
criteria for the study are focused on congenital or early 
onset severe phenotypes, and were specifi cally designed to 
maximise the chance of fi nding a highly penetrant 
monogenic cause for the child’s condition. The study was 
established with the dual aim of assisting the translation 
of new high-throughput genomic technologies into 
clinical practice, and elucidating the underlying genetic 
architecture of developmental disorders. Cambridge 
South Research Ethics Committee (REC) approved the 
feedback of potentially causal variants from DDD to the 
patients’ regional genetics centre, whose responsibility it 
is to assess and validate the fi ndings before communicating 
them to the families with appropriate counselling 
regarding recurrence risk, likely prognosis, and potential 
clinical management. The judgment not to feed back 
incidental fi ndings was REC-approved, and the protocol 
and patient information sheets clearly state that “incidental 
fi ndings will not be reported back in the DDD study”. 
Nonetheless, we developed a parallel research study to 
investigate attitudes towards feeding back a broader range 
of genomic results to research participants.16,17
We outline a process to identify and report likely causal 
variants (pertinent fi ndings) in individual patients, and 
summarise the results to date. There are many diff erent 
classes of disease-causing genetic variation, of which 
some are observed infrequently (eg, uniparental disomy, 
in which both copies of a single chromosome are 
inherited from one parent, which occurs in fewer than 
one in 1000 individuals18), whereas others are observed in 
huge numbers (eg, single DNA base changes, of which 
every individual has millions in their genome). Diff erent 
genetic changes need diff erent analysis methods; in 
particular, more numerous forms of genetic variation 
need a scalable automated approach. We describe the 
workfl ow we have developed to achieve a scalable 
genome-wide diagnostic analysis, focusing particularly 
on the automated part of a larger workfl ow, and we show 
the clinical usefulness of this workfl ow using data for 
1133 probands with severe undiagnosed developmental 
disorders as an example.
Methods
Clinical data collection
We developed a workfl ow to facilitate patient recruitment, 
sample tracking, data generation, data analysis, variant 
fi ltering, manual curation, and feedback of results 
(fi gure 1; appendix 1). Clinically ascertained undiagnosed 
patients meeting the recruitment criteria (severe 
undiagnosed neurodevelopmental disorder and/or 
congenital anomalies, abnormal growth parameters, 
dysmorphic features, and unusual behavioural pheno-
types) were recruited to the DDD study by their UK NHS 
or Irish Regional Genetics Service, who also recorded 
clinical information and phenotypes using the Human 
Phenotype Ontology (HPO)19 via a secure web portal 
within the DECIPHER database.20 A team of research 
coordinators (typically research nurses and genetic 
counsellors) working in each of the regional services 
provided essential support with informed consent, 
sample collection, and data entry (antenatal and growth 
data, developmental milestones, family history, previous 
genetic testing, etc) with the patient’s phenotype being 
entered by their clinical geneticist. The study has UK 
Research Ethics Committee approval (10/H0305/83, 
granted by the Cambridge South REC, and GEN/284/12 
granted by the Republic of Ireland REC).
For more on the DDD study see 
www.ddduk.org
For the DECIPHER database see 
https://decipher.sanger.ac.uk
Figure 1: Study workfl ow
SNV=single nucleotide variant. Indel=insertion or deletion. CNV=copy number variant. UPD=uniparental disomy. 
Patient recruitment
Clinical data
Selective variant
validation
Automated variant
analysis:
 (1) annotation
 (2) filtering
 (3) prioritisation
Phenotypes Family history
Genomic data
SNVs,  indels,  CNVs UPD, mosaicism
Manual review
Reporting
Diagnostic confirmation and families informed
Articles
www.thelancet.com   Vol 385   April 4, 2015 1307
Genomic assays
Saliva samples from patients and their parents were 
collected (Oragene DNA collection kits, DNA Genotek, 
Kanata, ON, Canada) and DNA extracted 
(QIAsymphony, Qiagen, Venlo, Netherlands); 
blood-derived DNA from the child was also provided by 
the regional genetics laboratories. DNA samples from 
patients and their parents were analysed at the 
Wellcome Trust Sanger Institute with microarray 
analysis (Agilent 2x1M array CGH [Santa Clara, CA, 
USA] and Illumina 800K SNP genotyping [San Diego, 
CA, USA]) to identify copy number variants (CNVs) in 
Figure 2: Variant fi ltering logic for clinical reporting within the study
Genomic variants were fi ltered on the basis of six factors, of which the fi rst fi ve were automated and the fi nal one was done manually: (1) frequency, prevalence of the variant in the general population (MAF 
≤1%); (2) function, most severe predicted functional consequence, such as LOF, defi ned by specifi c sequence ontology terms (transcript ablation, splice donor variant, splice acceptor variant, stop-gained, 
frameshift variant, stop-lost, initiator codon variant, in-frame insertion, in-frame deletion, missense variant, transcript amplifi cation, and coding sequence variant); (3) location, genomic location compared 
with DDG2P of published genes; (4) variant type, genotype (eg, heterozygous or homozygous) and loss or gain for small CNVs (which were only considered when they contained entire genes in which LOF 
or dominant negative mutations had been previously reported, and gains were only considered when they overlapped genes in which increased gene dosage mutations had been previously reported); 
(5) inheritance, aspects of the pipeline that are dependent on inheritance information derived from parental data are shaded; and (6) phenotype, patient phenotype was manually compared against 
published phenotypes for a particular gene. MAF=minor allele frequency. CNV=copy number variant. LOF=loss of function. DDG2P=Developmental Disorders Genotype-to-Phenotype database.
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the child, and exome sequencing (Agilent SureSelect 
55MB Exome Plus with Illumina HiSeq) to investigate 
single nucleotide variants (SNVs), small insertion-
deletions (indels), and CNVs in coding regions of the 
genome (appendix 1). Putative de novo sequence 
variants identifi ed using DeNovoGear21 were validated 
with targeted Sanger sequencing. The population 
prevalence (minor allele frequency) of each variant in 
nearly 15 000 samples from diverse populations was 
recorded, and the eff ect of each genomic variant was 
predicted with the Ensembl Variant Eff ect Predictor 
(VEP version 2.6)22 (appendix 1).
Variant fi ltering
An automated variant fi ltering pipeline was used to 
narrow down the number of putative diagnostic variants 
(fi gure 2). First, common (>1% minor allele frequency) 
and non-functional (not protein-altering) variants were 
fi ltered out. Second, potentially pathogenic variants in 
known disease genes were selected in by comparison 
against an in-house database of genes consistently 
implicated in specifi c developmental disorders, the 
Developmental Disorders Genotype-to-Phenotype data-
base (DDG2P). This database includes more than 
1000 genes that have been consistently implicated in 
specifi c developmental disorders and is updated regularly 
with newly implicated genes (table 1; appendix 1; 
appendix 2). Each gene in DDG2P is associated with a 
specifi c developmental phenotype or syndrome via a 
particular genetic mechanism (autosomal dominant, 
autosomal recessive, or X-linked) and mutation 
consequence on the gene product (loss of function, 
activating mutation, increased gene dosage, etc). The use 
of DDG2P enabled any rare variant in a known DD gene 
with a predictable eff ect on the gene product to be fl agged 
on the basis of inheritance, genotype, and likely 
mutational consequence. Large, rare CNVs overlapping 
non-DDG2P genes were also fl agged based on a series of 
size thresholds (>100 kb for losses and >250 kb for gains 
where the inheritance was either de novo or segregated 
with disease, and >500 kb for any genic CNV for which 
the inheritance was unclear).
Sharing of results
Flagged variants were manually reviewed in a weekly 
multidisciplinary team meeting including clinical 
geneticists and genetic scientists to assess their 
analytical and clinical validity. Patients’ detailed clinical 
presentation and family history were compared against 
published clinical features for each gene containing 
fl agged variants, to evaluate the likely relevance in 
that specifi c patient. When there were suffi  ciently 
overlapping clinical features, the variant (chromosome, 
position, gene[s], allele, genotype, inheritance, and 
most severe predicted consequence) was approved for 
reporting to the regional genetics service via the 
patient’s referring clinician. Variants were deposited 
into the patient’s record via the secure study web 
portal DECIPHER, where they could be viewed in an 
interactive genome browser to enable local evaluation, 
diagnostic laboratory validation, and discussion with 
the family as appropriate. Anonymised variants were 
made publicly accessible after a short holding period (to 
ensure the opportunity for families to be informed 
before release). Full genomic datasets were also 
deposited in the European Genome-Phenome Archive 
in accordance with the REC approval for the study.
Role of the funding source
The funders of the study did not contribute to the study 
design, data collection, data analysis, data interpretation, 
report writing, or the decision to submit this paper for 
publication. The corresponding author had full access to 
all the data in the study and fi nal responsibility for the 
decision to submit for publication.
Results
To achieve equity of access for all undiagnosed families 
with developmental disorders in the British Isles, every 
UK NHS regional genetics service was involved 
in supporting and setting up the study; Ireland was 
subsequently added after the study had started. Almost 
all consultant clinical geneticists (more than 180) across 
all 24 regional genetics services in the UK and Ireland 
have recruited families to the DDD study, with the help 
of local research coordinators (typically research nurses 
or genetic counsellors). Around 2000 families were 
recruited in the fi rst year of the study, rising to more 
than 8000 within 3 years. Among the fi rst 1133 complete 
family trios (child, mother, and father), the male-to-female 
ratio among the probands was 51:49 and the median age 
at last clinical assessment was 5·5 years (SD 4·0, range 
0–16). 121 (11%) children had one parent aff ected with a 
(typically milder) developmental phenotype, and 23 (2%) 
had both parents aff ected with developmental phenotypes 
(most often mild intellectual disability). Before entering 
DDD, 868 (77%) of the cohort had received clinical 
microarray testing, 633 (56%) had at least one targeted 
genetic test, and 522 (46%) had received both. Across the 
cohort, 1435 unique phenotype terms of the roughly 
July, 
2012
November, 
2012
July, 
2013
November, 
2013
Total reportable genes* 819 875 1075 1128
Genes added ·· 60 201 60
Genes removed† ·· 4 1 7
 In addition to genes being added or removed, annotations for existing genes can 
also change (eg, to include multiple modes or mechanisms). The November, 2013 
version was used for the analysis presented here and includes 1128 reportable genes. 
DDG2P=Developmental Disorders Genotype-to-Phenotype database. *DDG2P also 
contains non-reportable categories when there is insuffi  cient evidence associating a 
gene and developmental disorder (appendix 1). †The selection of variants for 
reporting is based on the strongest available evidence of gene function and no 
variants yet reported have been retracted because of changes in the DDG2P list.
Table 1: Changes to DDG2P over time
See Online for appendix 2
For the European Genome-
Phenome Archive see www.ebi.
ac.uk/ega
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10 000 available in the HPO were used to describe clinical 
presentations, with a mode of 4 per proband (range 1–27); 
987 (87%) children had intellectual disability, 270 (24%) 
had a history of seizures, and 121 (11%) had a congenital 
heart defect (fi gure 3).
Around 80 000 genomic variants were identifi ed from 
exome sequencing and array comparative genomic 
hybridisation in each individual proband, of which on 
average 400 were rare and protein altering, and 
30 of these overlapped known DDG2P genes. Further 
fi ltering based on DDG2P categories resulted in a 
median of 10 fl agged SNVs and indels per proband in 
the absence of parental data (range 2–25). We further 
refi ned this to a median of 1 per proband (range 0–13) 
using inheritance information derived from parental 
data (fi gure 4). The diff erence between the number of 
variants with and without parental data is primarily due 
to heterozygous benign variants in dominant genes 
inherited from unaff ected parents (table 2). Probands 
with unaff ected parents had a mean of 0·9 (SD 0·9) 
variants fl agged, which increased to 3·2 (2·4) with one 
aff ected parent and 7·4 (2·7) with two aff ected parents 
(fi gure 4). In addition to SNVs and indels, a further 
0·2 CNVs per proband were fl agged.
All fl agged variants were automatically annotated with 
pathogenicity scores from two variant prioritisation 
algorithms (SIFT23 and PolyPhen24) and compared against 
the public Human Gene Mutation Database (HGMD) and 
the Leiden Open Variation Database (LOVD), which 
together contained only 14% of fl agged variants. The 
phenotypes recorded for each patient were compared 
against those previously published for patients with 
similar mutations in the same gene, using primarily 
DDG2P, PubMed, GeneReviews, and OMIM. If the 
patient’s phenotype was deemed to be inconsistent with 
the genetic change (on the basis of current knowledge of 
the phenotypic spectrum of that gene), the variant was not 
returned to the patient’s clinician. The manual review is 
the most human-intensive step of the workfl ow, but was 
essential for validation and improvement of the automated 
fi ltering and prevention of likely non-pathogenic and 
incidental fi ndings from being reported. We expedited the 
review of the variants in the most frequently observed 
genes by requiring specifi c clinical features (eg, deafness) 
that related to these genes to be noted in the patient. 
Figure 3: Representation of phenotypic diversity in cohort
Our patient cohort represents children with  a wide range of severe undiagnosed 
developmental disorders ascertained clinically across the UK.
Seizures (24%)
Intellectual disability or
developmental delay (87%)
Autism spectrum disorder (10%)
Congenital heart 
defects (11%)
Polydactyly (1%)
Hearing impairment (7%)
Oral cleft (6%)
Visual impairment (3%)
Scoliosis (5%)
Figure 4: Analysis of fl agged variants in all 1133 children excluding (red) and including (blue) fi ltering on the 
basis of parental genotypes and aff ected status (using the November 2013 version of DDG2P)
(A) Histogram of the number of fl agged single nucleotide variants and insertion-deletions in 1133 children with and 
without parental data. (B) Mean number of fl agged variants per child with and without parental data for families where 
neither, one, or both parents are aff ected by a developmental phenotype, subdivided by DDG2P genetic mechanism. 
Note that compound heterozygous variants are counted once. Red=proband-only analysis. Blue=family-trio analysis 
with parental genotype data. Filled=autosomal dominant DDG2P genes. Vertical stripes=autosomal recessive DDG2P 
genes. Horizontal stripes=X-linked DDG2P genes. DDG2P=Developmental Disorders Genotype-to-Phenotype database.
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Recent work has highlighted the need for caution in 
interpretation of X-linked causes of intellectual disability,25 
and we made the decision not to consider any inherited 
missense variants on the X-chromosome (except in 
patients with a family history of developmental disorders 
or when the variant itself was present in either HGMD or 
LOVD) because of the large number of variants but low 
prior probability of causality for this class of variation.
After automated variant fi ltering, we manually reviewed 
1696 candidate variants in 1133 family trios and reported 
317 likely diagnostic SNVs, indels, and CNVs (table 3). 
Many of these diagnostic variants have subsequently 
been validated in an accredited diagnostic laboratory and 
communicated to individual families. Additionally, we 
found six likely pathogenic cases of uniparental disomy26 
and fi ve large mosaic chromosomal rearrangements 
(unpublished data). We reported two separate genetic 
fi ndings in 17 individual cases in which both fi ndings 
might contribute to the phenotype.
With 328 likely diagnostic or strongly contributory 
variants in 311 of 1133 children, our overall diagnostic rate 
is 27%. Within DDG2P genes, de novo variants accounted 
for 65% of our diagnoses across the cohort, and 92% of 
those that were validated were regarded as pathogenic 
(table 3). Although some genes were hit multiple times, 
we found a diagnosis in only 146 (13%) individual DDG2P 
genes, of which 92 were hit only once in this cohort 
(appendix 2). We assessed the performance of fi ve variant 
prioritisation tools23,24,27–29 to help to interpret the 
pathogenicity of missense variants (90% of fl agged 
variants), and found that PolyPhen and MutationTaster 
discriminated equally well between reported and 
non-reportable variants (appendix 1), but were nonetheless 
unable to predict the likely diagnostic variants accurately.
Discussion
We have developed and implemented a scalable workfl ow 
within a large-scale rare-disease research study to allow 
return of clinically pertinent genetic variants to clinicians 
and research participants (panel). The workfl ow is 
consistent with recently recommended guidelines for 
investigating causality of sequence variants in human 
disease,34,35 and we hope that it will act as a prototype for 
the translation of diagnostic genome sequencing into the 
clinic for a range of rare diseases. The semi-automated 
system we have described achieved a diagnostic yield of 
27% in previously investigated, yet undiagnosed, children 
with developmental disorders caused by variants in 
known genes across the genome (fi gure 5; appendix 1). 
The system is amenable to an iterative approach to 
reanalysis of patient data, and we expect that our 
diagnostic yield will increase in the coming years as a 
result of novel gene discovery (both within36 and outside 
of the DDD study) and ongoing improvements to the 
analysis algorithms and variant fi ltering rules.
De novo variants had by far the highest predictive 
value and diagnostic yield in our cohort, highlighting the 
value of having genotype data from both parents as well 
as the child. Of our 215 likely de novo diagnoses, 41 were 
CNVs and 174 were SNVs or indels, of which around half 
(90/174) were novel missense variants and half (84/174) 
were likely loss-of-function variants. Although we 
attempted to validate almost all putative de novo SNVs 
and indels in our cohort using targeted Sanger 
sequencing—the diagnostic gold standard—this process 
sometimes needed several attempts to optimise primer 
design and achieve high-quality data. Given appropriate 
quality thresholds and read depths in all three family 
members, we believe that trio exome sequencing is 
Family-trio analysis Proband-only analysis
Inherited De novo*
Autosomal dominant 473 193 9529
Autosomal recessive (homozygotes) 83 0 191
Autosomal recessive (compound 
heterozygotes)†
341 6 1071
X-linked dominant 38 21 269
X-linked recessive 322 15 387
Total 1257 235 11 447
Inherited variants in autosomal dominant DDG2P genes account for the main diff erence, in which only de novo variants 
and those inherited from an aff ected parent are likely to be of clinical interest. Around 90% of fl agged variants were 
predicted to be missense point mutations. DDG2P=Developmental Disorders Genotype-to-Phenotype database. 
*Before secondary validation by targeted Sanger sequencing. †Two or more likely pathogenic variants in diff erent copies 
of the same gene, counted once per compound variant.
Table 2: Total number of single nucleotide variants and insertion-deletions fl agged by the clinical 
reporting workfl ow in all 1133 probands (in the November, 2013 version of DDG2P) compared with the 
number of variants that would have been fl agged in the same probands in the absence of parental data
Reviewed (SNV, 
CNV)
Reported as 
likely 
diagnostic
Predictive 
value of fl ag 
(%)
Diagnostic yield 
(%; n=1133)
Autosomal dominant
De novo 242 (193, 49) 184 75% 16%
Inherited 528 (473, 55) 27 5% 2%
Autosomal recessive
De novo 6 (6, 0) 0 ·· ··
Inherited 425 (424, 1) 52 13% 5%
X-linked
De novo 41 (36, 5) 31 75% 3%
Inherited 371 (360, 11) 23 6% 2%
Uncertain inheritance 83 (0, 83) 0 ·· ··
Chromosomal events
Uniparental disomy ·· 6 ·· 0·5%
Mosaicism ·· 5 ·· 0·5%
Total 1696 328 19% 27%*
See appendix 2 for details of individual genes and phenotype classes. The predictive value is the probability that a 
fl agged variant was reported as likely diagnostic (reported or reviewed), and the diagnostic yield is the contribution of 
that type of variant to the overall diagnostic yield. Note that three pairs of siblings and two pairs of monozygotic twins 
received the same diagnosis. Only 14% of reported variants were present in the public Human Gene Mutation Database 
or Leiden Open Variation Database; 84% of fl agged variants present in these databases were not reported, because 
they did not appear to be relevant to the child’s phenotype. SNV=single nucleotide variant. CNV=copy number variant. 
*17 probands received two contributory pathogenic variants.
Table 3: Likely diagnoses in the fi rst 1133 families
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highly accurate for assessing de novo mutations, but 
that targeted Sanger validation will remain important for 
diagnostic confi rmation and cascade testing.
For families in which neither parent is aff ected by the 
same disorder, sequencing of parent–child trios rather 
than individual probands off ers around a ten-times 
reduction in the number of candidate variants, thus 
substantially increasing the speed and likelihood of 
reaching an accurate diagnosis. By contrast, when one or 
both parents are similarly aff ected, trio sequencing off ers 
only a three-times or 1·5-times reduction, respectively, and 
might therefore be less informative. By contrast with our 
trio-sequencing approach, de novo variants could instead 
be identifi ed in a stepwise fashion by exome sequencing of 
the proband, then assay of possibly pathogenic variants in 
both parents by targeted Sanger sequencing. However, in 
view of the rapidly decreasing cost of exome and genome 
sequencing (currently £1000–5000 per individual genome), 
trio exome sequencing could off er a more rapid, 
cost-eff ective, and scalable diagnostic method in addition 
to providing increased usefulness in research.
Since most of our cohort had received at least 
one genetic test before entering the study, introduction of 
exome sequencing early in the diagnostic pathway could 
substantially reduce costs and increase diagnostic yields 
versus current clinical practice. Additionally, a small but 
growing number of childhood developmental disorders 
are amenable to existing therapeutic interventions, and 
early treatment off ers substantial benefi ts in preventing 
irreversible clinical manifestations of the condition. 
Currently, 82 reportable DDG2P genes are associated 
with inborn errors of metabolism, which are causally 
related to intellectual disability, and are potentially 
amenable to therapy.37 To date, fi ve DDD children have a 
diagnostic variant in one of these treatable ID genes 
(DHCR7, IVD, LMBRD1, MTR, and SLC2A1) and might 
be suitable for either dietary restriction, supplementation, 
or pharmacological intervention.
When developing our clinical feedback policy, our aim 
was to maximise likely diagnoses while minimising 
incidental fi ndings, and we were conscious of the fact 
that clinical teams have neither the resources nor the 
remit to attempt to validate multiple variants of uncertain 
signifi cance in every patient. Like any medical test, the 
variant fi ltering process necessitates a trade-off  between 
sensitivity and specifi city, and any change to the analytical 
pipeline will potentially alter this balance. With an 
ever-expanding set of genes implicated in developmental 
disorders, and in light of the fact that around 80% of our 
fl agged variants did not appear to be relevant to the 
child’s developmental disorder, we hope to use 
the manually curated results presented here to refi ne the 
variant fi ltering rules further. Specifi cally, we expect to be 
able to lower the frequency threshold to 0·1% for 
dominantly inherited variants and, following an analysis 
of variant prioritisation methods (appendix 1), to use 
PolyPhen to exclude low-scoring inherited missense 
variants predicted to be benign. Although we plan to 
automate more of the clinical reporting process, we 
expect that some variants will always need expert 
gene-specifi c clinical and scientifi c interpretation.
Because of the large number of rare variants in every 
genome that are unrelated to disease, a genotype–
phenotype database (such as DDG2P) is crucial to allow 
novel variants to be prioritised on the basis of current 
knowledge of gene–disease associations and allelic 
requirements. In principle this approach could be applied 
to any medical specialism for the diagnosis of highly 
penetrant genetic conditions. Although it is possible to use 
a generic genotype-to-phenotype database for variant 
fi ltering based on a broad phenotype (ie, developmental 
disorders), detailed phenotypes are crucial for assignment 
of likely patho genicity to candidate variants. Fewer 
candidate variants could be fl agged by use of a smaller, 
more targeted list, and restriction of the assay to only this 
list of genes could potentially reduce the cost. We used the 
DDG2P database to allow return of variants when the 
patient’s phenotypes, developmental milestones, and 
morphometric data were consistent with published reports 
(this approach was not intended to allow association of 
new phenotypes with known genes, which will need 
further research). However, the value of whole genome or 
exome sequencing as compared with targeted gene panels 
For more on existing 
therapeutic interventions see 
http://www.treatable-id.org
Panel: Research in context
Systematic review
Trio exome sequencing is a highly successful research tool for new gene discovery.2 A 
recent health technology assessment concluded that there is “scarce evidence supporting 
the use of whole exome sequencing for etiologic diagnosis in patients with ID/DD”, and 
warned that this technology presents “ethical dilemmas related to incidental fi ndings in 
the analysis of genetic material in these patients”.30 A systematic review was not done, 
but we are aware of two smaller studies that have shown the likely usefulness of trio 
exome sequencing for clinical diagnosis of children with severe intellectual disability, 
including 51 patients from Germany or Switzerland31 and 100 patients from Nijmegen 
(Netherlands).5 Clinical investigation of 410 rare disease patients from the University of 
California32 achieved a 31% diagnostic rate for trio-based exome sequencing, and a large 
single-centre study of 2000 rare disease patients from Baylor (USA)33 reported a 
diagnostic rate of 25% using exome sequencing of the proband followed by targeted 
follow-up testing in the parents. 
Interpretation
Deciphering Developmental Disorders (DDD) is the fi rst nationwide exome sequencing 
study. It involves more than 1000 children with undiagnosed developmental disorders and 
their parents, combining genome-wide data from high-resolution microarrays and trio 
exome sequencing to maximise detection of potentially pathogenic variants. It achieved a 
consistent diagnostic rate while demonstrating a scalable, collaborative model for 
translational research. The informatics workfl ow developed by DDD has addressed one of 
the key ethical challenges raised by massively parallel sequencing technologies and, by 
using a clinically targeted analysis, shown that incidental fi ndings can be minimised. The 
DDD study will continue to recruit throughout the UK and Ireland until April, 2015, and 
aims to reach 12 000 patients; we expect to continue to improve our analysis workfl ow 
and increase the diagnostic rate higher than 30% as novel causal genes are discovered and 
incorporated into diagnostic analyses, allowing existing patient data to be reinterpreted.
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lies primarily in the research potential for gene discovery,36 
and the clinical usefulness of enabling future diagnoses to 
be made in current patients from existing data. This 
diagnostic benefi t is already apparent within our cohort, in 
which, on average, 20 new disease-implicated genes are 
published and added to DDG2P per month, making 
iterative analysis across the entire genomic dataset, 
coupled with automated variant fi ltering and re-reviewing, 
essential to maximise the diagnostic benefi t.
An outstanding question remains regarding whether 
researchers should actively search for so-called incidental 
fi ndings38 and thus undertake genomic screening of 
medically relevant genomic variation as recommended 
in standard clinical practice by the American College 
of Medical Genetics and Genomics.39 We note that 
searching for incidental fi ndings in this manner is a 
choice not a prerequisite of whole-genome sequencing, 
because the analysis can be entirely diagnostically 
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Figure 5: Genetic diagnoses associated with broad phenotype categories
Circos-style plot representing the genetic heterogeneity within developmental disorders, showing individual diagnoses in known Developmental Disorders 
Genotype-to-Phenotype database genes, which links the genomic location of each gene with some key phenotypes in each child. Phenotypes are listed outside the 
widest arc of the circle, chromosome numbers are indicated outside the smaller arc, and individual gene names are listed inside. Links are coloured by phenotype 
group. See appendix 2 for details of the diagnoses. ID=intellectual disability. CHD=congenital heart defect. ASD=autism spectrum disorders. Deaf=hearing 
impairment. Cleft=oral cleft. VI=visual impairment. MC=microcephalic dwarfi sm. PD=polydactyly.
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targeted (as we have shown). At the outset of DDD, we 
could not be confi dent that actively screening for 
additional incidental fi ndings unrelated to the child’s 
developmental disorder would be in the best interests of 
the patients and families within DDD, particularly in 
view of the paucity of data regarding the true signifi cance 
of such variants ascertained in individuals with no 
known previous risk of the cognate disease. Additionally, 
such screening could potentially undermine established 
clinical practice with respect to screening of children for 
adult-onset conditions.
Nonetheless, furnished with supplementary 
genotype-to-phenotype databases or specifi c variant 
lists, the analytical procedure we have described could 
be adapted to allow simultaneous opportunistic 
screening for many conditions, if this were deemed to 
be ethically appropriate and evaluation showed that 
there was evidence of benefi t to support this approach.8 
However, the infrastructure needed to create and 
support this workfl ow is considerable, and substantial 
investment of staff  time at all levels is needed to 
ensure that it is accurate and robust. Hundreds of 
individuals were involved in data entry, generation, 
management, processing, analysis, interpretation, 
and dissemination within DDD, including around 
15 full-time staff  with a dedicated laboratory and 
priority access to a high-performance computing 
cluster. Around 75 h were spent manually reviewing 
the fl agged variants in meetings that were attended by 
between two and eight people including at least one 
consultant clinical geneticist, and assessing the 
clinical relevance of rare functional variants even in 
well-known developmental disorder genes was often 
very challenging. Interpretation of variants relating to 
many other diseases in the absence of known 
symptoms or family history would be even harder, 
particularly in the absence of robust data concerning 
population-ascertained penetrance, and additional 
disease-specifi c expertise would no doubt be needed. 
For these reasons, we chose to focus on identifying 
pertinent fi ndings within the DDD study to maximise 
diagnostic yield and drive research into the underlying 
causes of developmental disorders.
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